Leap Therapeutics (LPTX) to Release Earnings on Monday

Leap Therapeutics (NASDAQ:LPTX) is projected to post its quarterly earnings results before the market opens on Monday, March 17th. Analysts expect Leap Therapeutics to post earnings of ($0.39) per share for the quarter.

Leap Therapeutics Stock Up 2.3 %

Shares of NASDAQ LPTX opened at $0.40 on Friday. Leap Therapeutics has a 52 week low of $0.39 and a 52 week high of $4.79. The stock has a market capitalization of $15.33 million, a price-to-earnings ratio of -0.21 and a beta of 0.35. The firm has a 50-day simple moving average of $1.23 and a 200-day simple moving average of $2.34.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. HC Wainwright cut shares of Leap Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday, January 29th. Baird R W cut shares of Leap Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, January 29th. Finally, Robert W. Baird cut shares of Leap Therapeutics from an “outperform” rating to a “neutral” rating and dropped their price objective for the company from $9.00 to $1.25 in a report on Wednesday, January 29th.

About Leap Therapeutics

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.